ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
August 06, 2022 13:16 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 06, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022 08:15 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
May 25, 2022 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
May 24, 2022 12:15 ET
|
Phathom Pharmaceuticals
Results from an investigational Phase 3 PHALCON-EE trial demonstrating superior healing at week 2 in patients with LA Grade C/D (moderate-to-severe) erosive esophagitis and superior maintenance of...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
May 03, 2022 17:40 ET
|
Phathom Pharmaceuticals
VOQUEZNA TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple...
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
March 14, 2022 08:02 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
March 01, 2022 16:04 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
October 24, 2021 15:30 ET
|
Phathom Pharmaceuticals
Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical ResearchPhase 1 population PK data abstract concludes the...
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
October 21, 2021 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
October 18, 2021 07:00 ET
|
Phathom Pharmaceuticals
Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phasesVonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus...